Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study
Related Articles
Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes
We appreciate the interest in our research1 of subthalamic nucleus (STN) deep brain stimulation (DBS) in early-stage Parkinson disease (PD). As noted in our publication,…
Reader Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes
We have followed with great interest the pilot trial on subthalamic nucleus deep brain stimulation (DBS) for early-stage Parkinson disease (PD). The 5-year outcomes of…
Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes
We appreciate the interest in our research of deep brain stimulation in early-stage Parkinson disease (PD).1 Bradykinesia and tremor are both troubling cardinal motor features…
Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia
Objective Progranulin-related frontotemporal dementia (FTD-GRN) is a fast progressive disease. Modelling the cascade of multimodal biomarker changes aids in understanding the aetiology of this disease…
Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis
Objective We aimed to investigate the validity of urinary N-terminal titin fragment as a biomarker for amyotrophic lateral sclerosis (ALS). Methods We consecutively enrolled patients…
English
العربية
简体中文
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
Responses